Cardiometabolic Risk in Type 2 Diabetes: What Can the PPAR-g Agonists Teach Us?

UKPDS 35: Impact of Increasing A1c on Cardiovascular Disease in T2DM

Insulin Resistance Is Associated With or Directly Responsible for Factors Causing Atherothrombosis

UKPDS 35: Effect of A1c on MI and Microvascular Events

UKPDS 80: 10-Year Follow-up Study of Intensive Glycemic Control in T2DM

Incidence of CV Events in Subjects With T2DM vs the Nondiabetic CAD Population

PPAR-g Agonists: Lipoprotein Effects

PROactive: Time to Secondary CV Composite End Point

FDA Statistical Review and Evaluation Meta-analysis of Pioglitazone

CV Events With PPAR-g Agonists

Genes Uniquely Regulated by the TZDs

Pioglitazone Induces IkBa Protein Expression In Vivo in a PPAR-a-Dependent Manner

The Concept of Dual PPAR-a/g Agonists

Effect of Muraglitazar on Composite CV Endpoints

Effect of Tesaglitazar on Serum Creatinine and Glomerular Filtration

SYNCHRONY: Effect of Aleglitazar vs Pioglitazone on A1c

SYNCHRONY: Effect of Aleglitazar vs Pioglitazone on LDL-C and HDL-C

ALECARDIO: Aleglitazar in Patients With T2DM and ACS

Program Summary